According to AlphaMoat, in 2026-08 Galux (galux.co.kr) received 2,608 monthly visits (-64.8% MoM) — ranked #14,488 of 17,407 AI websites with traffic data, and #2,536 of 3,173 in Industry Services; its largest market is South Korea (100.0% of visits).
What is Galux
Galux is a biotechnology company headquartered in Seoul, South Korea, operating the proprietary protein-therapeutics design platform GaluxDesign, which fuses artificial intelligence with physical principles, trains models from first principles, and achieves cross-modal de novo protein design, validated on the most challenging antibody de novo design.
- 01GaluxDesign targets protein and antibody design with cross-modal generality and precision
- 02it is used for antibody de novo design in new-drug development
- 03the company collaborates with multiple global pharmaceutical and research institutions to advance AI-driven antibody-drug R&D
- 04and it offers integrated “discovery-to-design” platform capabilities
As a biotechnology company, it creates value through R&D collaborations and partnerships via its network; the website does not publish standardized product pricing, and the page lists no explicit currency price figures.
12-Month Traffic Trend
Visits by Country · Top 5
Popular in Industry Services
Data month: 2026-08 · Visit figures are third-party traffic estimates aggregated monthly — best for scale and trends. Multiple domains of the same product are merged. See methodology.